Detailed information
Notice
The information is provided in the language in which it was submitted by the researcher.
- Project title:
- Neurochemical and behavioural characterisation of a novel Dopamine Transporter Deficiency Syndrome mouse model.
- Principal investigator(s):
- Salahpour, Ali
- Co-investigator(s):
- Tyndale, Rachel F
- Supervisors:
- N/A
- Institution paid:
- University of Toronto
- Research institution:
- University of Toronto
- Department:
- Pharmacology and Toxicology
- Program:
- Project Grant
- Competition (year/month):
- 201709
- Assigned peer review committee:
- Behavioural Sciences - A: Neurobiological Basis of Behavioural Processes
- Primary institute:
- Neurosciences, Mental Health and Addiction
- Primary theme:
- Biomedical
- Term (yrs/mths):
- 5 yrs 0 mth
- CIHR contribution:
- Contributors:
- Amount:
- $814,725
- Equipment:
- $0
- External funding partner(s):
- Partner Name:
- N/A
- Amount:
- N/A
- Equipment:
- N/A
- External applicant partner(s):
- Partner Name:
- N/A
- Amount:
- N/A
- Equipment:
- N/A
- External in-kind partner(s):
- Partner Name:
- N/A
- Amount:
- N/A
- Equipment:
- N/A
- Keywords:
- Behavioural Pharmacology; Bupropion; Dopamine Transporter; Dopamine Transporter Deficiency Syndrome; Ibogaine; Neurochemistry; Pharmacological Chaperones
- Abstract/Summary:
- Dopamine transmission in the brain is a tightly regulated process, and alterations in dopamine signaling result in several disease with enormous human and economic burden, including schizophrenia, ADHD, Bipolar disorder, Parkinson's disease and dyskinesias. One of the key regulators of dopamine transmission is the plasma membrane dopamine transporter, DAT, which transports released dopamine back into the neuron. In addition to the above prevalent diseases, there is also a rare, fatal disease caused by mutations in the dopamine transporter, called dopamine transporter deficiency syndrome. We hypothesize that several disease states could be corrected by increasing the protein levels of the dopamine transporter. Drugs that increase dopamine transporter activity could potentially treat conditions such as such as dopamine transporter deficiency syndrome. We have worked to identify drugs that would increase the levels and activity of the dopamine transporter, and have discovered that the prescribed drug bupropion increases dopamine transporter levels and activity. Recently, we generated a transgenic mouse model of dopamine transporter deficiency syndrome. Our proposed research is designed to uncover the pathophysiology of this by studying these new transgenic animals. Also, we will measure whether bupropion will be able to have therapeutic effect in this new mouse model. Positive results from our studies could be quickly translated into the clinic, since bupropion is already an approved drug and used in humans.
- Version:
- 20250311.1